Fund managers skittish over Levi's long-term growth prospects

Levi Strauss & Co's is betting it can convince investors there is still plenty of global growth left for the 165-year old company, but fund managers fret the iconic blue jeans maker's stock may be too pricey to generate a decent return.

Levi Strauss shares surge 31 percent in stock market return

Shares in Levi Strauss & Co surged 31 percent in their debut on Thursday, giving the jeans maker a market value of $8.7 billion and suggesting strong investor appetite before much-awaited listings from Lyft and Uber.

Wall Street powers world stocks; Brexit weighs on sterling

A measure of stocks across the globe rose in a volatile session on Thursday, led by gains on Wall Street, while the dollar rallied as traders continued to digest the Federal Reserve's uber-dovish stance.

Boeing to offer safety feature as standard in 737 MAX software upgrade

Boeing Co plans to offer as standard a safety feature that might have warned earlier of problems that possibly played a role in the doomed Ethiopian and Indonesian plane crashes that killed almost 350 people, two officials briefed on the matter said Thursday.

Boeing to mandate safety alert in 737 MAX software upgrade: sources

Boeing Co will mandate a previously optional cockpit warning light as part of a forthcoming software update to the 737 MAX fleet that was grounded in the wake of two fatal crashes, two officials briefed on the matter said Thursday.

Ethiopia says U.S., EU, French teams helping analyze crash black boxes

Ethiopia has begun examining cockpit voice and flight data recordings from doomed Ethiopian Airlines flight 302 and is working with U.S., EU and French experts, the Ministry of Transport said on Thursday.

Boeing slows 737 factory work for three days after recent delays

Boeing Co said on Thursday that production lines will not "pulse" or move airframes forward for three days next week at its 737 factory to allow workers to catch up on work that was previously delayed.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

Tech dominates Wall Street rally in wake of dovish Fed statement

Technology stocks surged on Thursday, leading Wall Street higher as jitters over the Federal Reserve's warning of an economic slowdown were allayed by upbeat economic data.

Union fund adviser CtW questions Lyft's path to profitability ahead of IPO

Union pension fund adviser CtW Investment Group said on Thursday Lyft Inc "faces an all-but-insurmountable barrier" to profitability due to issues with the ride-hailing company's pricing strategy and new regulations driving costs higher.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS